Teva Continues To Grow By M&A Not R&D

Teva Pharmaceutical Industries continues to favour inorganic growth from M&A over in-house research and development (R&D). However, large debts from acquisitions, below consensus sales results and the possibility that it will soon face generic competition for its biggest earner - Copaxone (glatiramer acetate) - will worry investors.

To read the full article, please choose one of the following options: